US stock index futures rise sharply following Gilead Sciences’ statement on remdesivir

The National Institute of Allergy and Infectious Diseases’ (NIAID) trial of the antiviral remdesivir for the treatment of COVID-19 met its primary endpoint, Gilead Sciences Inc. said in a statement on Wednesday. The company also published its results from the Phase-3 trial with key takeaways found below. Tonight, risk-on with the expectation of economic recovery …

US stock index futures rise sharply following Gilead Sciences’ statement on remdesivir Read More »